Article Sidebar
Published:
Jun 25, 2024DOI:
10.4314/tjpr.v23i5.2Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of anti-CD3-EGFR bispecific antibody-labeled DCCIK immune cells on proliferation of lung cancer cells
Abstract
Purpose: To investigate the effect of DC-CIK immune cells labeled with anti-CD3-EGFR bispecific antibody (BSAB) on the proliferation of lung cancer (LC) cells in order to generate data useful for enhancing the therapy of LC.
Methods: The anti-CD3 and anti-EGFR monoclonal antibodies were labeled on the surface of DC-CIK cells using chemical coupling method. Successful preparation of anti-CD3-EGFR BSAB was determined using SDS-PAGE. Two groups of cells were used: labeled group and a DC-CIK group. The cytotoxic effect on A549 LC cells was determined in vitro, and the tumor inhibition capacity was determined in 30 nude mice with LC.
Results: The killing rate of EGFR-positive A549 cells in labeled group was more severe than the killing rate in DC-CIK cells (p < 0.05). Cellular growth rate was significantly lesser in labelled A549 LC cells than in DC-CIK group. After 2 months of treatment, nude mouse tumor size in labeled group was smaller than the tumor volume in DC-CIK group. No obvious adverse reactions (ARs) were observed in both groups.
Conclusion: In vitro, CD3-EGFR BSAB-labeled DC-CIK immune cells produce cytotoxic effect and inhibit the proliferation of LC cells, while in vivo studies reveal that the cells produce good therapeutic effect on LC.
